文献速递系统性红斑狼疮

奥法妥木单抗用于对利妥昔单抗过敏的系统性红斑狼疮患者的B细胞清除

Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

单中心回顾性病例系列纳入16例因严重输注反应对利妥昔单抗不耐受的SLE患者,2012至2015年接受奥法妥木单抗治疗。14/16例输注耐受良好,12/14例实现B细胞清除,伴ANA、抗dsDNA抗体及补体水平等血清学指标改善;狼疮肾炎患者中半数6个月内达肾脏缓解。长期随访(中位28个月)报告5例III级感染,无恶性肿瘤或死亡。

要点

  • 对利妥昔单抗严重输注反应的SLE患者中,奥法妥木单抗输注耐受良好14/16例。
  • 14例可评估者中12例实现B细胞清除,血清学活动指标改善。
  • 狼疮肾炎患者中半数6个月内达肾脏缓解,5例疾病进展对环磷酰胺强化免疫抑制无反应。

核心结论

  • 在这组长病程、经充分预治疗的SLE队列中,奥法妥木单抗是耐受良好、安全且有效的利妥昔单抗替代B细胞清除治疗。

研究设计与样本

  • 单中心回顾性病例系列,纳入2012至2015年间接受奥法妥木单抗治疗的16例SLE患者。
  • 患者均为对利妥昔单抗不耐受(因严重输注反应)者。

主要发现

  • 16例中14例奥法妥木单抗输注耐受良好,该14例中位年龄34岁(范围19-55),中位SLE病程9.2年(范围0.6-28.5)。
  • 队列经充分预治疗,50%有既往环磷酰胺暴露,既往利妥昔单抗中位累积剂量4 g(范围1-6)。
  • 14例中12例用于狼疮肾炎,1例用于肾外 flare,1例用于缓解维持。
  • 14例中12例实现B细胞清除,重建动力学与本中心既往利妥昔单抗治疗队列相当,并伴ANA、抗dsDNA抗体及补体水平等血清学疾病活动指标改善。
  • 狼疮肾炎患者中半数在6个月内达肾脏缓解;5例出现对环磷酰胺强化免疫抑制无反应的疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: B cell depletion, most commonly with rituximab, is an evolving therapeutic approach in SLE. Infusion reactions after rituximab are common, and may prevent re-treatment in patients who previously demonstrated beneficial response. We have used ofatumumab, a fully humanized anti-CD20 mAb, as an alternative B cell-depleting agent in patients with SLE who are rituximab-intolerant due to severe infusion reactions. METHODS: A single-centre retrospective case series of 16 patients were treated with ofatumumab for SLE between 2012 and 2015. RESULTS: Ofatumumab infusion was well tolerated in 14/16 patients, in whom the median age was 34 (range 19-55) and the median duration of SLE 9.2 years (0.6-28.5). The cohort was heavily pre-treated, with 50% having prior CYC exposure, and a median cumulative dose of prior rituximab 4 g (1-6). Twelve patients were treated for LN, one for extra-renal flare and one for remission maintenance. B cell-depletion was achieved in 12/14 patients, with comparable reconstitution kinetics to a previous cohort treated with rituximab at our centre, and was associated with improvements in serological markers of disease activity, including ANA, anti-dsDNA antibody and complement levels. Half of the patients with LN achieved renal remission by 6 months. Progressive disease that was unresponsive to augmented immunosuppression with CYC was seen in five patients. During long-term follow-up (median 28 months), five grade III infections were reported, and there were no malignancies or deaths. CONCLUSION: In this pre-treated cohort with long-standing SLE, ofatumumab was a well-tolerated, safe and effective alternative to rituximab for B cell-depletion therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Masoud S, McAdoo SP, Bedi R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018. PMID: 29562252. doi:10.1093/rheumatology/key042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。